Fig. 1.

Potency, efficacy, and synergy of buparlisib, selumetinib, and pazopanib in four TNBC human-derived cancer cell lines in vitro. (A) Utilized cell lines, with their molecular classifications and relevant known mutational statuses. Drug response curves of SUM149 (149), MDA-MB-231Br (231Br), MDA-MB-468 (468), and MDA-MB-436 (436) TNBC cells after 72 hours with (B) buparlisib, (C) selumetinib, or (D) pazopanib. Synergy fraction affected (FA) versus combination index (CI) curves quantification for combined (E) buparlisib+selumetinib or (F) selumetinib+pazopanib in 149, 231Br, 468, and 436. CI categories: synergistic: <0.1–0.9, additive: 0.9–1.1, antagonistic: >1.1.